November 24, 2016 - By Peter Erickson · 0 Comments
Baxter International Inc (NYSE:BAX) institutional sentiment increased to 0.83 in Q2 2016. Its up 0.15, from 0.68 in 2016Q1. The ratio improved, as 300 investment managers opened new and increased stock positions, while 438 cut down and sold their equity positions in Baxter International Inc. The investment managers in our partner’s database now hold: 437.24 million shares, down from 466.81 million shares in 2016Q1. Also, the number of investment managers holding Baxter International Inc in their top 10 stock positions decreased from 19 to 16 for a decrease of 3. Sold All: 75 Reduced: 363 Increased: 233 New Position: 67.
Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The company has a market cap of $24.85 billion. The Firm operates through two divisions: Hospital Products and Renal. It has a 5.24 P/E ratio. The Company’s Hospital Products business makes IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products.
The stock increased 0.82% or $0.38 on November 23, hitting $46.56. About 2.32 million shares traded hands. Baxter International Inc (NYSE:BAX) has risen 7.48% since April 22, 2016 and is uptrending. It has outperformed by 2.07% the S&P500.
Analysts await Baxter International Inc (NYSE:BAX) to report earnings on February, 7. They expect $0.52 EPS, up 20.93% or $0.09 from last year’s $0.43 per share. BAX’s profit will be $277.53 million for 22.38 P/E if the $0.52 EPS becomes a reality. After $0.56 actual EPS reported by Baxter International Inc for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.
According to Zacks Investment Research, “Baxter engages in the worldwide development, manufacture and distribution of a diversified line of products, systems and services used primarily in the health-care field. The company’s products are used by hospitals, clinical and medical research laboratories, blood and dialysis centers, rehabilitation centers, nursing homes, doctors’ offices and by patients, at home, under physician supervision.”
Third Point Llc holds 22.37% of its portfolio in Baxter International Inc for 51.90 million shares. Sector Gamma As owns 1.08 million shares or 9.87% of their US portfolio. Moreover, Rit Capital Partners Plc has 7.42% invested in the company for 192,000 shares. The United Kingdom-based Veritas Asset Management Llp has invested 4.54% in the stock. 13D Management Llc, a New York-based fund reported 225,687 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 1 insider sale for $201,588 net activity.
Ratings analysis reveals 45% of Baxter International’s analysts are positive. Out of 11 Wall Street analysts rating Baxter International, 5 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $33 while the high is $58. The stock’s average target of $45.67 is -1.91% below today’s ($46.56) share price. BAX was included in 20 notes of analysts from July 30, 2015. The firm has “Market Perform” rating by Leerink Swann given on Thursday, July 30. On Wednesday, May 4 the stock rating was initiated by Evercore with “Buy”. The rating was maintained by Barclays Capital on Tuesday, August 11 with “Overweight”. Wells Fargo initiated Baxter International Inc (NYSE:BAX) on Thursday, October 13 with “Outperform” rating. The stock of Baxter International Inc (NYSE:BAX) earned “Overweight” rating by Piper Jaffray on Monday, November 16. The rating was reinitiated by JP Morgan on Monday, June 6 with “Neutral”. The rating was reinitiated by Credit Suisse with “Neutral” on Monday, August 10. RBC Capital Markets maintained Baxter International Inc (NYSE:BAX) on Wednesday, February 3 with “Sector Perform” rating. The stock has “Sector Perform” rating given by RBC Capital Markets on Wednesday, October 26. UBS initiated Baxter International Inc (NYSE:BAX) on Tuesday, September 22 with “Neutral” rating.
Baxter International Inc., incorporated on October 19, 1931, through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Firm operates through two divisions: Hospital Products and Renal. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision. The Firm makes products in approximately 30 countries and sells them in approximately 120 countries.
Another recent and important Baxter International Inc (NYSE:BAX) news was published by Fool.com which published an article titled: “Baxter International Inc Gets More Efficient” on October 26, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Peter Erickson